Market closed
Prelude Therapeutics/$PRLD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Ticker
$PRLD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
128
Website
PRLD Metrics
BasicAdvanced
$72M
Market cap
-
P/E ratio
-$1.77
EPS
1.55
Beta
-
Dividend rate
Price and volume
Market cap
$72M
Beta
1.55
52-week high
$6.80
52-week low
$0.80
Average daily volume
577K
Financial strength
Current ratio
7.037
Quick ratio
6.913
Long term debt to equity
9.852
Total debt to equity
11.594
Management effectiveness
Return on assets (TTM)
-39.29%
Return on equity (TTM)
-66.64%
Valuation
Price to revenue (TTM)
32.169
Price to book
0.46
Price to tangible book (TTM)
0.46
Price to free cash flow (TTM)
-0.897
Growth
Earnings per share change (TTM)
-17.04%
3-year earnings per share growth (CAGR)
-6.57%
What the Analysts think about PRLD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Prelude Therapeutics stock.
PRLD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PRLD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PRLD News
AllArticlesVideos
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
GlobeNewsWire·2 weeks ago
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
GlobeNewsWire·4 weeks ago
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Prelude Therapeutics stock?
Prelude Therapeutics (PRLD) has a market cap of $72M as of December 22, 2024.
What is the P/E ratio for Prelude Therapeutics stock?
The price to earnings (P/E) ratio for Prelude Therapeutics (PRLD) stock is 0 as of December 22, 2024.
Does Prelude Therapeutics stock pay dividends?
No, Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Prelude Therapeutics dividend payment date?
Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Prelude Therapeutics?
Prelude Therapeutics (PRLD) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.